Mylan sued over alleged EpiPen exclusivity rebates
EpiPens (Credit: Greg Friese)
Sanofi sued EpiPen maker Mylan on Monday for allegedly suppressing competition in the market for drugs used to treat severe allergic reactions, by creating a rebate program for third party payors specifically conditioned on payors exclusively purchasing EpiPen.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10